---

Clinical Report: Tailoring Treatment for Myelofibrosis

Background

Myelofibrosis is a heterogeneous clonal myeloid neoplasm that presents significant challenges in treatment due to its variable biological characteristics. Understanding the differences between primary and secondary MF is crucial for effective management and personalized treatment approaches. The integration of molecular profiling and clinical assessments is essential for optimizing patient outcomes.

Data Highlights

Recent studies indicate that approximately 20-30% of patients with myelofibrosis may have a mutation in the JAK2 gene, while others may present mutations in CALR or MPL. Clinical trials have shown that ruxolitinib can improve symptoms and quality of life in patients with myelofibrosis, with a response rate of around 50-60% in those treated. Additionally, the median overall survival for patients undergoing allogeneic hematopoietic cell transplantation is reported to be around 5-10 years, depending on various risk factors.

Key Findings

• Precision medicine in MF incorporates marrow morphology, molecular profiles, and symptom burden.

• Ruxolitinib is the first-line treatment for symptomatic proliferative disease, with alternatives like fedratinib and pacritinib for specific patient needs.

• Allogeneic hematopoietic cell transplantation remains the only curative option and should be considered early for high-risk patients.

• Emerging AI applications may enhance precision care but require validation and oversight before routine use.

• Prognostic models derived from primary MF may not be directly applicable to secondary MF, necessitating careful interpretation.

Clinical Implications

Clinicians should adopt a comprehensive approach to diagnosing and treating myelofibrosis, considering both molecular and clinical factors.

Conclusion

Advancements in precision medicine for myelofibrosis highlight the need for individualized treatment strategies based on a thorough understanding of disease biology and patient-specific factors.

Related Resources & Content

1. Blood Cancer Journal, 2021 -- Advancements in Acute Myeloid Leukemia: Current Insights and Future Perspectives

2. The ASCO Post, 2025 -- Machine Learning Program May Enhance Transplantation Risk Assessment in Patients With Myelofibrosis

3. The ASCO Post, 2026 -- ASH 2025: Myelofibrosis Roundup

4. Oncology Clinical Pathways, 2024 -- Myelofibrosis Clinical Pathways

5. International Journal of Cancer, 2025 -- The German ONKOPEDIA Guideline for Myelofibrosis

6. British Society for Haematology -- The management of myelofibrosis: A British Society for Haematology Guideline

7. PubMed -- Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations

8. the asco post — ASH 2025: Myelofibrosis Roundup

9. Oncology Clinical Pathways

10. The German ONKOPEDIA Guideline for Myelofibrosis in 2025—Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO) - Griesshammer - International Journal of Cancer - Wiley Online Library

11. The management of myelofibrosis: A British Society for Haematology Guideline

12. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group - PubMed

13. Table 77.1, [Prognosis risk scores and transplant specific (MTSS) score for myelofibrosis]. - The EBMT Handbook - NCBI Bookshelf

14. ASH Draft Recommendations for Guidelines on Myelofibrosis

15. The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis | Blood Cancer Journal

16. OJJAARA (momelotinib) tablets, for oral use — Highlights of Prescribing Information

17. VONJO (pacritinib) Highlights of Prescribing Information

18. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial - PMC

19. Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis - ScienceDirect

20. Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial | Journal of Clinical Oncology

---